Day One Biopharmaceuticals (NASDAQ:DAWN) Cut to “Hold” at Zacks Research

Zacks Research cut shares of Day One Biopharmaceuticals (NASDAQ:DAWN) from a strong-buy rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports.

Several other research firms also recently weighed in on DAWN. Wedbush lifted their target price on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. increased their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. TD Cowen assumed coverage on Day One Biopharmaceuticals in a report on Tuesday, January 13th. They set a “buy” rating and a $34.00 target price for the company. Finally, Needham & Company LLC reduced their price target on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $26.14.

Day One Biopharmaceuticals Trading Down 0.5%

Shares of NASDAQ:DAWN opened at $10.60 on Wednesday. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -10.29 and a beta of -1.26. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $13.20. The business has a 50-day moving average price of $10.71 and a 200 day moving average price of $8.80.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The company had revenue of $53.72 million for the quarter, compared to analysts’ expectations of $49.81 million. As a group, equities research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jeremy Bender sold 15,459 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $179,324.40. Following the completion of the transaction, the chief executive officer owned 204,603 shares in the company, valued at approximately $2,373,394.80. This trade represents a 7.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Lauren Merendino sold 5,814 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the transaction, the insider directly owned 60,157 shares of the company’s stock, valued at approximately $697,821.20. This represents a 8.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,461 shares of company stock worth $422,948 over the last ninety days. Company insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada lifted its position in shares of Day One Biopharmaceuticals by 40.4% during the 1st quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock worth $1,474,000 after purchasing an additional 53,459 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Day One Biopharmaceuticals by 601.4% during the 1st quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock worth $4,906,000 after buying an additional 530,429 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Day One Biopharmaceuticals by 6.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock worth $302,000 after acquiring an additional 2,149 shares in the last quarter. Millennium Management LLC boosted its position in shares of Day One Biopharmaceuticals by 587.2% during the 1st quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock worth $10,468,000 after acquiring an additional 1,127,995 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Day One Biopharmaceuticals by 232.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock valued at $12,449,000 after acquiring an additional 1,097,679 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Q4 2025 commercial strength and aggressive 2026 guidance — Net product revenues were $52.8M (up ~36% sequentially) and management guided U.S. net product revenues of $225M–$250M for 2026 (midpoint implies ~50% growth over 2025). Company also has several clinical catalysts (Emi‑Le and DAY‑301 readouts in 2026; FIREFLY‑2 possible mid‑2027 readout) that could uplift valuation if positive. Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
• Neutral Sentiment: Market sentiment/context — Coverage pieces note improving confidence in broader Nasdaq futures and summarize analyst commentary; these provide background but no single catalyst. DAWN Gaining Confidence In Nasdaq Futures
• Neutral Sentiment: Short‑interest data looks unreliable/insignificant in the latest snapshot (reported 0 shares / data anomalies), so short pressure is not a clear driver today. (No meaningful short‑squeeze signal.)
• Negative Sentiment: Analyst estimate cuts from HC Wainwright — The firm sharply lowered Q1–Q4 2026 and FY2026 EPS forecasts (FY2026 now forecast at -$0.41 vs prior -$0.07) and trimmed out‑year estimates, although it retained a Buy rating and $22 target. The revisions signal weaker near‑term profitability expectations and add downward pressure. HC Wainwright Research Note (DAWN)
• Negative Sentiment: Zacks downgraded DAWN from “strong‑buy” to “hold,” which likely reinforced selling by momentum or quant traders sensitive to rating changes. Zacks Research
• Neutral Sentiment: Analyst roundups (e.g., Benzinga) summarize the mixed views; no single consensus change beyond the above. What Analysts Are Saying About Day One Biopharmaceutical Stock

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.